ReviewSoy isoflavone supplementation could reduce body weight and improve glucose metabolism in non-Asian postmenopausal women—A meta-analysis
Introduction
After menopause, the incidence of cardiovascular disease (CVD) and metabolic diseases increases significantly, partly in relation to advanced age and partly to estrogen deficiency [1]. Overweight and central obesity, diet changes, and lack of exercise concur to alter women's glucose tolerance and increase insulin resistance during the post menopausal period. Impaired glucose tolerance and diabetes mellitus, which are risk factors in the process of CVD, may be found in nearly 20% of women aged 55 to 65 years [2]. Hormone replacement therapy has been shown to mediate clinical cardiovascular risk factors, including reducing body weight [3], increasing insulin-sensitivity [4], and improving blood lipid levels, but the controversial effects of hormone replacement therapy has been overwhelming. It is necessary to find an alternative method to decrease the risk of CVD, which occurs after menopause in women.
Soy is a rich source of the polyphenolic isoflavones genistein and daidzein. Isoflavones are structurally similarly to estradiol and have a high binding affinity for the primary estrogen receptor in the vascular wall. From a research point of view, previous animal research in our team showed that soy isoflavones could decrease body weight and insulin level [5]. Choi et al. [6] found that isoflavone played important roles in the regulation of glucose homeostasis in type 1 diabetic mice. Further cross-sectional studies have suggested that postmenopausal women who consumed a high soy diet had a lower body mass index (BMI) and lower fasting insulin compared to those who consumed no soy [7].
On the basis of laboratory and observational evidence, several longitudinal studies in postmenopausal women have examined the relationship between soy isoflavone supplementation and risk factors for CVD, such as body weight, lipids, and glucose metabolism, but the results are controversial. Some research suggested a reduction in body weight [8], [9], fasting blood glucose [10], [11], and insulin level [10], [11], while others did not [12], [13], [14], [15], [16].
Clinical trial studies used various amounts of isoflavones with various periods of treatment in postmenopausal women. The purpose of this meta-analysis was to synthesize the evidence from randomized controlled trials (RCTs) by performing a meta-analysis to assess the effects of soy isoflavone supplementation on the CVD risk factors such as body weight, fasting blood glucose, and insulin level in non-Asian postmenopausal women.
Section snippets
Literature search
A literature search was carried out in PubMed, EMBASE, and Cochrane databases to identify all relevant RCTs about the effects of soy isoflavone supplementation on body weight, blood glucose, and insulin from 1970 to October 2010 in the non-Asian population. We used the following medical subject heading (MeSH) terms and/or text words: “body weight” [MeSH Terms] AND “isoflavones” [MeSH Terms]; “blood glucose” [MeSH Terms] AND “isoflavones” [MeSH Terms]; “insulin” [MeSH Terms] AND “isoflavones”
Characteristics of studies and quantitative synthesis
A total of 594, 142, and 404 studies were identified from the primary computerized literature search for potential relevant studies. The excluded studies included reviews, animal experiments, duplicated publications, studies not interested in this relationship investigation, and no isoflavone supplemented or combined with other treatments. Finally, 9, 11, and 11 studies for body weight, blood glucose, and insulin levels separately were included for the meta-analysis (Fig. 1). In some studies,
Discussion
A recently published meta-analysis in 2010 by Ricci et al. [22] reported that isoflavone use was not associated with a significant glycemia reduction in perimenopausal and postmenopausal non-Asian women. Our meta-analysis yielded completely significantly different results. In this meta-analysis, significant changes were found in body weight, blood glucose level, and fasting insulin level with soy isoflavone supplementation compared with the placebo control group in the non-Asian postmenopausal
Acknowledgments
This work was supported by the Natural Science Foundation of China (30972439).
References (30)
- et al.
Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects
Maturitas
(1995) - et al.
Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women
J Nutr
(2001) - et al.
Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women
Fertil Steril
(2007) - et al.
The effect of soy protein with or without isoflavones relative to milk protein on plasma lipids in hypercholesterolemic postmenopausal women
Am J Clin Nutr
(2001) - et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
(1996) - et al.
Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women
Maturitas
(2006) - et al.
Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production
Am J Clin Nutr
(2006) - et al.
Effects of soy protein and isoflavones on glycemic control and insulin sensitivity: a 6-mo double-blind, randomized, placebo-controlled trial in postmenopausal Chinese women with prediabetes or untreated early diabetes
Am J Clin Nutr
(2010) - et al.
A meta-analysis of the effect of soy protein supplementation on serum lipids
Am J Cardiol
(2006) - et al.
Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause
J Endocrinol Invest
(2004)
Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women
Int J Obes Relat Metab Disord
The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study
Angiology
Isoflavone reduces body weight by decreasing food intake in ovariectomized rats
Ann Nutr Metab
Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice
Diabetes Metab Res Rev
The differential effect of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women: relationship with the metabolic status
J Clin Endocrinol Metab
Cited by (0)
This work was supported by the Natural Science Foundation of China (30972439) and Youth Fund of Public Health College of HMU.